A. Hipper

684 total citations
21 papers, 391 citations indexed

About

A. Hipper is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, A. Hipper has authored 21 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 8 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in A. Hipper's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). A. Hipper is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). A. Hipper collaborates with scholars based in Germany, United States and Estonia. A. Hipper's co-authors include Karl Kunzelmann, R. Greger, Marcus Mall, G Isenberg, Andreas Büsch, Dieter C. Gruenert, Sven Kathöfer, Matthias Briel, Sigrid Ricken and Roland Nitschke and has published in prestigious journals such as Journal of Clinical Oncology, FEBS Letters and Annals of Oncology.

In The Last Decade

A. Hipper

17 papers receiving 380 citations

Peers

Countries citing papers authored by A. Hipper

Since Specialization

Citations

This map shows the geographic impact of A. Hipper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Hipper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Hipper more than expected).

Fields of papers citing papers by A. Hipper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Hipper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Hipper. The network helps show where A. Hipper may publish in the future.

Co-authorship network of co-authors of A. Hipper

This figure shows the co-authorship network connecting the top 25 collaborators of A. Hipper. A scholar is included among the top collaborators of A. Hipper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Hipper. A. Hipper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315) 2024 ·International Journal of Cancer ·Martin Sebastian, Wilfried Eberhardt, (unknown), Steffen Dörfel, (unknown), (unknown), Christoph Losem, Martina Jänicke, (unknown), Stefan Zacharias, (unknown), A. Hipper, (unknown), Annalen Bleckmann, (unknown), (unknown), Christian Grah, Annette Müller, Frank Griesinger, Michael Thomas, (unknown)	0
2	1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315) 2022 ·Annals of Oncology ·Martin Sebastian, Frank Griesinger, (unknown), Steffen Dörfel, (unknown), (unknown), (unknown), Martina Jänicke, (unknown), Stefan Zacharias, A. Hipper, (unknown), Annalen Bleckmann, (unknown), (unknown), (unknown), (unknown), Wilfried Eberhardt, Michael Thomas	1
3	1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C 2020 ·Annals of Oncology ·Frank Griesinger, Wilfried Eberhardt, Petra Hoffknecht, Martin Metzenmacher, Thomas Wehler, Konrad Kokowski, (unknown), Wolfgang Schütte, Martina Jänicke, (unknown), Stefan Zacharias, A. Hipper, (unknown), Wilko Weichert, (unknown), (unknown), (unknown), Tobias Dechow, Martin Sebastian, (unknown)	1
4	Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) 2019 ·Annals of Oncology ·Frank Griesinger, Wilfried Eberhardt, Harald-Robert Bruch, (unknown), (unknown), Norbert Marschner, Martina Jänicke, (unknown), (unknown), (unknown), (unknown), A. Hipper, Wilko Weichert, Parvis Sadjadian, Martin Metzenmacher, Wolfgang Gleiber, Martin Sebastian, Mike Thomas	1
5	Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) 2019 ·Annals of Oncology ·Martin Sebastian, Wilfried Eberhardt, Christoph Losem, (unknown), Christoph Maintz, Norbert Marschner, Martina Jänicke, (unknown), (unknown), (unknown), (unknown), A. Hipper, Wilko Weichert, Petra Hoffknecht, Christian Grah, Achim Rittmeyer, Frank Griesinger, Mike Thomas	1
6	Molecular testing, frequency of molecular alteraions and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany. First results from the prospective German Registry CRISP (AIO-TRK-0315) 2018 ·Pneumologie ·Frank Griesinger, (unknown), Arnd Nusch, Marcel Reiser, Christoph Losem, Norbert Marschner, Martina Jänicke, (unknown), (unknown), (unknown), A. Hipper, Maike de Wit, Martin Metzenmacher, Cornelius F. Waller, Wilko Weichert, Martin Sebastian, Michael Thomas	2
7	Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315) 2018 ·Annals of Oncology ·Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, Marcel Reiser, (unknown), Norbert Marschner, (unknown), (unknown), (unknown), (unknown), (unknown), A. Hipper, Wilko Weichert, Achim Rittmeyer, (unknown), Cornelius F. Waller, (unknown)	2
8	Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany: First results from the prospective German Registry CRISP (AIO-TRK-0315). 2018 ·Journal of Clinical Oncology ·Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, Marcel Reiser, (unknown), Norbert Marschner, Martina Jänicke, (unknown), (unknown), (unknown), (unknown), A. Hipper, Wilko Weichert, Achim Rittmeyer, Martin Metzenmacher, Cornelius F. Waller, Martin Sebastian, Michael Thomas	3
9	MA08.02 Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315 2017 ·Journal of Thoracic Oncology ·Frank Griesinger, Wilfried Eberhardt, Norbert Marschner, Martina Jänicke, A. Hipper, (unknown), Martin Sebastian, Michael Thomas, Peter Schirmacher	0
10	Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315. 2016 ·Journal of Clinical Oncology ·Frank Griesinger, Wilfried Eberhardt, Norbert Marschner, Martina Jänicke, (unknown), (unknown), (unknown), A. Hipper, Martin Sebastian, Michael Thomas	1
11	Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial. 2011 ·Journal of Clinical Oncology ·Susanna Hegewisch‐Becker, Christian Lerchenmüller, Anja Welt, Thomas Decker, Marianne Just, Claus-Christoph Steffens, A. Hipper, Norbert Marschner	4
12	Cyclic mechanical strain decreases the DNA synthesis of vascular smooth muscle cells 2000 ·Pflügers Archiv - European Journal of Physiology ·A. Hipper, G Isenberg	40
13	Cyclic mechanical strain decreases the DNA synthesis of vascular smooth muscle cells 2000 ·Pflügers Archiv - European Journal of Physiology ·A. Hipper, G Isenberg	2
14	The cystic fibrosis transmembrane conductance regulator attenuates the endogenous Ca 2+ activated Cl - conductance of Xenopus oocytes 1997 ·Pflügers Archiv - European Journal of Physiology ·Karl Kunzelmann, Marcus Mall, Matthias Briel, A. Hipper, Roland Nitschke, Sigrid Ricken, R. Greger	52
15	Wild type but not ΔF508 CFTR inhibits Na⁺ conductance when coexpressed in Xenopus oocytes 1996 ·FEBS Letters ·Marcus Mall, A. Hipper, R. Greger, Karl Kunzelmann	129
16	Culture-dependent expression of Na + conductances in airway epithelial cells 1996 ·Pflügers Archiv - European Journal of Physiology ·Karl Kunzelmann, Sven Kathöfer, A. Hipper, D. C. Gruenert, R. Greger	2
17	Culture-dependent expression of Na+ conductances in airway epithelial cells 1996 ·Pflügers Archiv - European Journal of Physiology ·Karl Kunzelmann, Sven Kathöfer, A. Hipper, Dieter C. Gruenert, R. Greger	43
18	cAMP Stimulation of CFTR-expressing Xenopus oocytes activates a chromanol-inhibitable K+ conductance 1996 ·Pflügers Archiv - European Journal of Physiology ·Marcus Mall, Karl Kunzelmann, A. Hipper, R. Greger, Andreas Büsch	39
19	Blockade of epithelial Na+ channels by triamterenes — Underlying mechanisms and molecular basis 1996 ·Pflügers Archiv - European Journal of Physiology ·Andreas Büsch, H. Suessbrich, Karl Kunzelmann, A. Hipper, R. Greger, Siegfried Waldegger, E. Mutschler, Bernd Lindemann, Florian Läng	27
20	Mutations in the putative pore‐forming domain of CFTR do not change anion selectivity of the cAMP activated Cl⁻ conductance 1995 ·FEBS Letters ·A. Hipper, Marcus Mall, R. Greger, Karl Kunzelmann	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact